Caribou Biosciences Advances CAR-T Therapies, Launches GALLOP Trial

Caribou Biosciences, Inc. announced the beginning of the GALLOP Phase 1 clinical trial of CB-010 with lupus nephritis and extrarenal lupus patients. This phase II trial represents a new arena for the company to explore beyond its advanced CAR-T cell therapies in hematologic malignancies. The trial demonstrates that Caribou is ready to tackle unmet needs with tailored CRISPR-edited treatments.

The company also revealed an ambitious pipeline for 2025, based on the expectation of clinical data readouts in the CAR-T programs, including CB-010 in CD-19 relapsed large B cell lymphoma and CB-011 in relapsed and refractory multiple myeloma. The HLA matching strategy is expected to unlock a Phase 3 trial of CB-010 in the second half of 2025. During the event, CEO Dr. Rachel Haurwitz highlighted that Caribou is among those that heavily invest in allogeneic CAR-T therapies that provide quick and affordable solutions to patients and healthcare systems globally.